8-KOther Events

BIOGEN INC. 8-K Report (Apr 30, 2004)

Filed April 30, 2004For Securities:BIIB

Summary

This 8-K filing by Biogen Idec Inc. (BIIB) on April 30, 2004, primarily serves to furnish a press release dated the same day. The press release, embedded within the filing, contains information regarding the company's results of operations and financial condition. As this is an 8-K filed specifically to include a press release, investors should refer to the press release content for the core operational and financial updates. The filing itself does not contain detailed financial statements or operational discussions but rather points to the press release as the primary source of this information.

Key Highlights

  • 1The filing is an 8-K Current Report for Biogen Idec Inc. (BIIB).
  • 2The report was filed on April 30, 2004.
  • 3The primary purpose of this filing is to include a press release dated April 30, 2004.
  • 4The press release contains "Disclosure of Results of Operations and Financial Condition."
  • 5The press release is furnished under Item 12 of Form 8-K.
  • 6Information provided is not deemed "filed" for purposes of Section 18 of the Exchange Act.
  • 7The filing references Exhibit 99.1, which is the Press Release dated April 30, 2004.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally submit Biogen Idec's press release dated April 30, 2004, which provides updates on the company's results of operations and financial condition.

The detailed financial and operational information is contained within the press release dated April 30, 2004, which is attached as Exhibit 99.1 to this 8-K filing. Investors should review this press release for specific details.

No, according to the disclaimer in the filing, the press release is being furnished and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. It also states it will not be incorporated by reference into other filings.

This disclosure typically covers a company's recent financial performance, revenue, expenses, profitability, and key operational highlights or challenges. For specific details related to Biogen Idec's situation on April 30, 2004, investors must consult the press release itself.